AnaptysBio, Inc.

No trades
See on Supercharts
Market capitalization
398.628MUSD
−5.41USD
−128.724MUSD
10.287MUSD
Beta
0.33

About AnaptysBio, Inc.

CEO
Daniel R. Faga
Headquarters
San Diego
Employees (FY)
96
Founded
2005
ISIN
US0327241065
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Performance
Revenue to profit conversion
Earnings
‪0‬
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Interactive Brokers
Stocks, Futures, Bonds
4.4Very Good

See all brokers